On Monday, February 23, 2026, Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organization (CDMO), announced that it has secured European Union Good Manufacturing Practice (EU GMP) certification for two of its major facilities in Haridwar, Uttarakhand.
This dual certification is a significant regulatory leap, combining a successful renewal for its oral solids plant with a first-time “fresh” certification for its oral liquids facility.
Facility Breakthroughs: Haridwar Hub
The audits, conducted by the Bulgarian Drug Agency (BDA), validate Akums’ adherence to the world’s most stringent quality benchmarks.
- Plant 1 (Renewal): Dedicated to Oral Solid Dosage. The certification covers the manufacture and supply of tablets, hard gelatin capsules, and powder sachets.
- Plant 2 (Fresh Certification): Dedicated to Oral Liquid Dosage. This facility is now authorized to produce and supply solutions, syrups, and suspensions for the European market.
- CDMO Contract: Akums has already locked in a major European CDMO contract valued at €35 million (~₹315 crore) annually, which will be serviced from the newly certified Plant 2.
Strategic UK Entry: Rivaroxaban Approval
Parallel to the EU GMP milestone, Akums has secured its first UK MHRA (Medicines and Healthcare products Regulatory Agency) approval for Rivaroxaban, an oral anticoagulant used to treat blood clots.
- Market Impact: This marks Akums’ direct entry into the UK’s $2.6 billion anticoagulant market.
- The “Marketing Authorisation” (MA) Holder: Akums will act as the direct MA holder for the product, signaling a shift from a “behind-the-scenes” manufacturer to a visible global player.
Scale and Capacity (2026)
With these new approvals, Akums is leveraging its massive domestic base to fuel global exports.
| Metric | Status |
| Total Facilities | 14 Plants (12 Formulation, 2 API units). |
| Annual Capacity | 50+ Billion units (Formulations) and 737 MT (APIs). |
| Workforce | 16,000+ personnel. |
| Global Reach | Serving 1,500+ clients across 65+ countries. |
| Revenue (Q3 FY26) | ₹1,160 Crore (up 14.8% YoY). |
Leadership Perspectives
“We built scale, compliance, and credibility in India. Our vision now extends with the same commitment to Europe and the UK. What we have achieved domestically, we are determined to replicate globally.” — Sandeep Jain, Managing Director.
“Achieving certification across two facilities simultaneously underscores the maturity of our compliance and operational capabilities. This enables our partners to rely on us for consistent quality across multiple dosage forms.” — Sanjeev Jain, Co-Managing Director.